Inmune Stock Earnings Reports

INmune Bio reported strong program progress in Q1 2026 with CORDStrom (pobistrocel; commercial name Ebstracel for RDEB) as the near-term priority and a potential major value inflection through regulatory filings. Key regulatory milestones: the pediatric investigation plan (PIP) was submitted to the U.K. regulator and rapidly assessed with no substantial issues; the company expects to submit final PIP responses imminently. Manufacturing readiness advanced with the first of three process validation runs started on schedule and an amended material transfer agreement with the Anthony Nolan U.K. Cord Blood Bank executed to secure umbilical cord supply and enable U.S. lab testing per FDA requirements. INmune now expects to submit to the MHRA in early Q3 and is running EMA and FDA submission work in parallel (via TMC Pharma) to meet the previously described end-of-year filing timeline, targeting commercial manufacturing and supply in 2027. XPro work continues—additional MRI/myelin-preservation analyses from the MINDFuL study and exploration of rare-disease trials and partnering options are underway. Financials: Q1 net loss was ~$5.4M (vs. $9.7M prior year), R&D spend declined to ~$3.6M, G&A was ~$2.2M, cash and equivalents were ~$21.4M as of March 31, 2026, with a stated cash runway into Q1 2027. Outstanding shares: ~26.6M. Risks remain (as with any forward-looking development-stage biotech) including regulatory, manufacturing scale-up, financing and clinical outcomes.